The company's oncology portfolio is currently bolstered by lucrative drugs like Imbruvica and Venclexta. Its neuroscience portfolio, including drugs like Vraylar and Botox Therapeutic, is also ...

This exemption stands as a notable advantage for the company’s cancer therapy drug, Venclexta, potentially preserving its competitive positioning and pricing dynamics in a challenging environment.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.

By inhibiting BCL-2, Venclexta is designed to help reinitiate apoptosis in cancer cells. Venclexta is being co-developed by AbbVie and Roche. In the United States, it is jointly commercialized by ...

AbbVie (ABBV) recently submitted a Supplemental New Drug Application to the FDA for a new combination regimen targeting chronic lymphocytic leukemia, which accompanies positive Phase 3 trial ...

AbbVie (ABBV) recently submitted a Supplemental New Drug Application to the FDA for a new combination regimen targeting chronic lymphocytic leukemia, which accompanies positive Phase 3 trial outcomes.

"This FDA submission marks a milestone for CLL treatment with the potential approval for the first oral combination regimen of VENCLEXTA and acalabrutinib for previously untreated patients with ...

AbbVie has submitted a supplemental New Drug Application (sNDA) to the FDA for the approval of Venclexta (venetoclax) in combination with acalabrutinib in previously untreated patients with chronic ...

Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, as a part of the company's growing development programmefor ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer’s development portfolio is being present ...

Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study. In the high-dose cohort from the ongoing Phase Ib/IIa Brainshuttle AD ...

Roche Holding AG plans to test whether an experimental medicine can prevent Alzheimer’s disease symptoms in high-risk people, its latest investment in one of the most failure-prone areas of ...